Ascletis Raises $100MM To Deploy Its U.S.-China Hybrid Drug Development Model

In the latest and most ambitious attempt to create a new global pharma with one foot in China and one in the West, Ascletis Inc. has launched with a hybrid drug development model that has attracted $100 million in committed funding